-
Je něco špatně v tomto záznamu ?
Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme
D. Vagiannis, Z. Yu, E. Novotna, A. Morell, J. Hofman,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- benzamidy farmakologie MeSH
- buňky A549 MeSH
- buňky Hep G2 MeSH
- buňky MDCK MeSH
- chemorezistence účinky léků fyziologie MeSH
- cytochrom P-450 CYP3A * chemie metabolismus MeSH
- cytostatické látky farmakologie MeSH
- indazoly farmakologie MeSH
- inhibitory proteinkinas farmakologie MeSH
- lidé MeSH
- mnohočetná léková rezistence účinky léků fyziologie MeSH
- nádorové buněčné linie MeSH
- P-glykoproteiny antagonisté a inhibitory chemie metabolismus MeSH
- psi MeSH
- sekundární struktura proteinů MeSH
- simulace molekulového dockingu metody MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- psi MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Entrectinib is a new tyrosine kinase inhibitor that was recently approved for the treatment of ROS1-positive metastatic non-small cell lung cancer (NSCLC). In this study, we aimed to characterize its potential to act as a modulator of pharmacokinetic cytostatic resistance and perpetrator of drug interactions. In accumulation studies, entrectinib exhibited potent inhibition of ABCB1, while only moderate interaction was recorded for ABCG2 and ABCC1 efflux transporters. Furthermore, incubation assays revealed the potential of this drug to inhibit various recombinant cytochrome P450 enzymes, which can be ranked according to inhibitory affinities as follows: CYP2C8 ≈ CYP3A4 > CYP2C9 > CYP2C19 ≈ CYP3A5 > CYP2D6 > CYP2B6 > CYP1A2. Additionally, in silico docking analysis confirmed entrectinib's interactions with ABCB1 and CYP3A4 and resolved their possible molecular background. In subsequent drug combination experiments, we demonstrated the ability of entrectinib to synergize with daunorubicin in various ABCB1-expressing cellular models. Moreover, the comparative proliferation study results suggested that the anticancer efficacy of entrectinib is not affected by the functional presence of tested ABC transporters. In contrast to ABCB1-related data, no resistance reversal effect was recorded for the combination with docetaxel in HepG2-CYP3A4 cells. In the final experimental set, we observed no significant changes in ABCB1, ABCG2, ABCC1 or CYP3A4 gene expression in NSCLC cells exposed to entrectinib. In summary, our work indicates that entrectinib may be a perpetrator of clinically relevant pharmacokinetic drug interactions and modulator of ABCB1-mediated resistance. Our in vitro results might provide a valuable foundation for future clinical investigations.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027955
- 003
- CZ-PrNML
- 005
- 20210114152703.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcp.2020.114061 $2 doi
- 035 __
- $a (PubMed)32497550
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vagiannis, Dimitrios $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 245 10
- $a Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme / $c D. Vagiannis, Z. Yu, E. Novotna, A. Morell, J. Hofman,
- 520 9_
- $a Entrectinib is a new tyrosine kinase inhibitor that was recently approved for the treatment of ROS1-positive metastatic non-small cell lung cancer (NSCLC). In this study, we aimed to characterize its potential to act as a modulator of pharmacokinetic cytostatic resistance and perpetrator of drug interactions. In accumulation studies, entrectinib exhibited potent inhibition of ABCB1, while only moderate interaction was recorded for ABCG2 and ABCC1 efflux transporters. Furthermore, incubation assays revealed the potential of this drug to inhibit various recombinant cytochrome P450 enzymes, which can be ranked according to inhibitory affinities as follows: CYP2C8 ≈ CYP3A4 > CYP2C9 > CYP2C19 ≈ CYP3A5 > CYP2D6 > CYP2B6 > CYP1A2. Additionally, in silico docking analysis confirmed entrectinib's interactions with ABCB1 and CYP3A4 and resolved their possible molecular background. In subsequent drug combination experiments, we demonstrated the ability of entrectinib to synergize with daunorubicin in various ABCB1-expressing cellular models. Moreover, the comparative proliferation study results suggested that the anticancer efficacy of entrectinib is not affected by the functional presence of tested ABC transporters. In contrast to ABCB1-related data, no resistance reversal effect was recorded for the combination with docetaxel in HepG2-CYP3A4 cells. In the final experimental set, we observed no significant changes in ABCB1, ABCG2, ABCC1 or CYP3A4 gene expression in NSCLC cells exposed to entrectinib. In summary, our work indicates that entrectinib may be a perpetrator of clinically relevant pharmacokinetic drug interactions and modulator of ABCB1-mediated resistance. Our in vitro results might provide a valuable foundation for future clinical investigations.
- 650 _2
- $a buňky A549 $7 D000072283
- 650 _2
- $a P-glykoproteiny $x antagonisté a inhibitory $x chemie $x metabolismus $7 D018435
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a benzamidy $x farmakologie $7 D001549
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a cytochrom P-450 CYP3A $x chemie $x metabolismus $7 D051544
- 650 _2
- $a cytostatické látky $x farmakologie $7 D054697
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a mnohočetná léková rezistence $x účinky léků $x fyziologie $7 D018432
- 650 _2
- $a chemorezistence $x účinky léků $x fyziologie $7 D019008
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indazoly $x farmakologie $7 D007191
- 650 _2
- $a buňky MDCK $7 D061985
- 650 _2
- $a simulace molekulového dockingu $x metody $7 D062105
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 650 _2
- $a sekundární struktura proteinů $7 D017433
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Yu, Zhang $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 700 1_
- $a Novotna, Eva $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 700 1_
- $a Morell, Anselm $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
- 700 1_
- $a Hofman, Jakub $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic. Electronic address: jakub.hofman@faf.cuni.cz.
- 773 0_
- $w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 178, č. - (2020), s. 114061
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32497550 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152701 $b ABA008
- 999 __
- $a ok $b bmc $g 1608290 $s 1119135
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 178 $c - $d 114061 $e 20200601 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
- LZP __
- $a Pubmed-20210105